Skip to main content
Premium Trial:

Request an Annual Quote

GenTel BioSurfaces to Market and Sell Kreatech s ULS Labeling Kits

NEW YORK, Aug. 16 (GenomeWeb News) - GenTel BioSurfaces will market and sell ULS labeling reagent kits made by Kreatech Biotechnology, the companies said today.


The kits, which will be sold under the brand name Pandeia, are validated for use on GenTel's PATH protein microarray platform. They will be launched during the Chips to Hits conference in Bostonon Sept. 12, the company said.


For one- or two-color fluorescent profiling of the relative abundance of proteins using single capture antibody arrays, each protein sample is labeled with either ULS-biotin or ULS-fluorescein, and probed against the antibody microarray, the companies said in a statement.


The bound labeled proteins are detected using fluorescent Dy dyes made by Dyomics using either a streptavidin-Dy647 conjugate or an anti-fluorescein antibody-Dy547 conjugate. The processed microarray is scanned on a standard two-color fluorescent scanner. Kreatech, which holds a license from Dyomics, has sub-licensed the rights to market and sell Dyomics' dye conjugates to GenTel.


GenTel's PATH protein array surface technology consists of an ultra-thin nitrocellulose film used for multiplex immunoassays. ULS labels multiple amino acids, the companies said. The use of the ULS labeling system "further minimizes background noise using indirect fluorescence detection."

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.